ArticleLiver cancer2026

Lenvatinib versus Sorafenib in First-Line Treatment of Older Patients with Unresectable Hepatocellular Carcinoma: A Subgroup Analysis of the REFLECT Trial.

Masatoshi Kudo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.